BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27787353)

  • 1. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.
    Tsamandouras N; Guo Y; Wendling T; Hall S; Galetin A; Aarons L
    Pharmacogenet Genomics; 2017 Jan; 27(1):27-38. PubMed ID: 27787353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
    Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
    Li R; Barton HA
    Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
    Mirošević Skvrce N; Macolić Šarinić V; Šimić I; Ganoci L; Muačević Katanec D; Božina N
    Pharmacogenomics; 2015 Jul; 16(8):803-15. PubMed ID: 26086347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
    Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
    Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.
    Fukunaga K; Nakagawa H; Ishikawa T; Kubo M; Mushiroda T
    BMC Genet; 2016 Jun; 17(1):79. PubMed ID: 27296832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
    Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
    Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
    Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
    Wu HF; Hristeva N; Chang J; Liang X; Li R; Frassetto L; Benet LZ
    J Pharm Sci; 2017 Sep; 106(9):2751-2757. PubMed ID: 28385543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers.
    Zhao G; Liu M; Wu X; Li G; Qiu F; Gu J; Zhao L
    Pharmacogenomics; 2017 Jan; 18(1):65-75. PubMed ID: 27967318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
    Vora B; Brackman DJ; Zou L; Garcia-Cremades M; Sirota M; Savic RM; Giacomini KM
    Clin Transl Sci; 2021 Jul; 14(4):1431-1443. PubMed ID: 33931953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
    Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
    Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
    León-Cachón RBR; Bamford AD; Meester I; Barrera-Saldaña HA; Gómez-Silva M; Bustos MFG
    Sci Rep; 2020 Jun; 10(1):8900. PubMed ID: 32483134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.